Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 8Cytokine Release Syndrome 3Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neurilemmoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × siltuximab × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡